{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:06:28Z","timestamp":1761102388410},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2019,9]]},"abstract":"\n Background and Purpose\u2014<\/jats:title>\n We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation.<\/jats:p>\n <\/jats:sec>\n \n Methods\u2014<\/jats:title>\n New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 for nonvalvular atrial fibrillation, followed 1 year in the French Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (66 million people). R15 and R20 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high-dimensional propensity score. Hazard ratios (95% CIs) for stroke and systemic embolism, major bleeding, and death were computed using Cox proportional hazards or models by Fine and Gray during exposure.<\/jats:p>\n <\/jats:sec>\n \n Results\u2014<\/jats:title>\n \n In 31\u2009171 matched R20 and VKA, mean age, 71; 62% men; 76% with CHA\n 2<\/jats:sub>\n DS\n 2<\/jats:sub>\n -VASc \u22652; 5% HAS-BLED >3 (hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol); incidence rates for stroke and systemic embolism were 1.5% and 1.9% (hazard ratio, 0.79 [0.69\u20130.90]); major bleeding, 1.5% and 2.2% (0.67 [0.59\u20130.77]); death, 3.9% and 5.8% (0.67 [0.61\u20130.73]). In 23\u2009314 matched R15 and VKA patients, mean age, 80; 47% men; 93% with CHA\n 2<\/jats:sub>\n DS\n 2<\/jats:sub>\n -VASc \u22652 and 9% with HAS-BLED >3; incidence rates of stroke and systemic embolism were 2.3% and 2.1% (1.05 [0.92\u20131.21]); major bleeding, 2.4% and 2.9% (0.84 [0.74\u20130.96]); death, 9.1% and 10.8% (0.85 [0.79\u20130.90]). Numbers needed to treat to observe one fewer death (NNT) were 46 for R15 and 61 for R20.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions\u2014<\/jats:title>\n In real life in France over 2013 to 2015, R15 and R20 were at least as effective and safer than VKA.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration\u2014<\/jats:title>\n \n URL:\n http:\/\/www.encepp.eu<\/jats:ext-link>\n . Unique identifier: EUPAS14567.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1161\/strokeaha.119.025824","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:00:24Z","timestamp":1565254824000},"page":"2469-2476","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation"],"prefix":"10.1161","volume":"50","author":[{"given":"Patrick","family":"Blin","sequence":"first","affiliation":[{"name":"From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Universit\u00e9 de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[{"name":"H\u00f4pital Trousseau\u2013CHU de Tours, Service de cardiologie, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Fran\u00e7ois Rabelais, France (L.F.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dureau-Pournin","sequence":"additional","affiliation":[{"name":"From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Universit\u00e9 de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sacher","sequence":"additional","affiliation":[{"name":"IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Universit\u00e9\/Bordeaux University Hospital (CHU), Electrophysiology and Ablation Unit, Centre de recherche Cardio-Thoracique de Bordeaux, INSERM U1045, Universit\u00e9 de Bordeaux, France (F.S.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dallongeville","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Lille, Inserm U744, Unit\u00e9 d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, France (J.D.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Agn\u00e8s","family":"Bernard","sequence":"additional","affiliation":[{"name":"From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Universit\u00e9 de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis","family":"Lassalle","sequence":"additional","affiliation":[{"name":"From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Universit\u00e9 de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Droz-Perroteau","sequence":"additional","affiliation":[{"name":"From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Universit\u00e9 de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[{"name":"From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Universit\u00e9 de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.)"},{"name":"INSERM U1219, Universit\u00e9 de Bordeaux, France (N.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090041008"},{"key":"e_1_3_4_3_2","first-page":"CD001927","article-title":"Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.","author":"Aguilar MI","year":"2005","unstructured":"Aguilar, MI, Hart, R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005:CD001927.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.06.029"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12807"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.1.68"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17670-8"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04507.x"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12683"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.084"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.03.063"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1318"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13815"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2046"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.015710"},{"key":"e_1_3_4_20_2","first-page":"42","article-title":"Certification des comptes: une incitation \u00e0 la tra\u00e7abilit\u00e9 des processus de contr\u00f4le.","volume":"582","author":"Gilleron V","year":"2018","unstructured":"Gilleron, V, Gasnier-Duparc, N, Hebbrecht, G. Certification des comptes: une incitation \u00e0 la tra\u00e7abilit\u00e9 des processus de contr\u00f4le. Revue Hospitaliere de France. 2018;582:42\u201346.","journal-title":"Revue Hospitaliere de France"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000438859"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12143"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4690"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1214\/09-STS313"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a663cc"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000581"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1334-2"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2328"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr001"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13291"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00027-7"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3189"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j510"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008150"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.07.092"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017474"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003725"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.03.047"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.05.022"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008643"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.600"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.119.025824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T15:13:08Z","timestamp":1715613188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.119.025824"}},"subtitle":["A Population-Based New Users High-Dimensional Propensity Score Matched Cohorts Study"],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1161\/STROKEAHA.119.025824"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.119.025824","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"2019-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}